Company intelligence / Profile preview
Neukio Biotherapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Neukio Biotherapeutics develops next-generation allogeneic cell therapies using induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T cells engineered with chimeric antigen receptors (CARs). Their lead programs target solid tumors using scalable, off-the-shelf products enabled by proprietary gene-editing and manufacturing technologies. The company has rapidly advanced from founding in mid–2021 to having its first two candidates enter clinical trials by late–2024. No published human efficacy data yet; preclinical results support further development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic cell therapyiPSC-derived CAR-NK cellsiPSC-derived CAR-T cellsGene-edited immune cell therapies
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Neukio Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neukio Biotherapeutics.